Top 5 Stocks to Buy Now
→ The Treasury just bought its own debt (From Golden Portfolio) (Ad)tc pixel Free VCYT Stock Alerts

Veracyte (VCYT) Competitors

Veracyte logo
$53.79 +0.60 (+1.13%)
Closing price 06/23/2026 04:00 PM Eastern
Extended Trading
$53.74 -0.05 (-0.09%)
As of 06/23/2026 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

VCYT vs. TWST, BTSG, FMS, HIMS, and PACS

Should you buy Veracyte stock or one of its competitors? MarketBeat compares Veracyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veracyte include Twist Bioscience (TWST), BrightSpring Health Services (BTSG), Fresenius Medical Care AG & Co. KGaA (FMS), Hims & Hers Health (HIMS), and PACS Group (PACS). These companies are all part of the "medical" sector.

How does Veracyte compare to Twist Bioscience?

Veracyte (NASDAQ:VCYT) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Veracyte has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

Veracyte has a net margin of 16.25% compared to Twist Bioscience's net margin of -19.85%. Veracyte's return on equity of 9.07% beat Twist Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte16.25% 9.07% 8.38%
Twist Bioscience -19.85%-26.73%-19.15%

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M8.30$66.35M$1.0949.35
Twist Bioscience$376.57M14.06-$77.67M-$1.33N/A

In the previous week, Veracyte had 3 more articles in the media than Twist Bioscience. MarketBeat recorded 9 mentions for Veracyte and 6 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.02 beat Veracyte's score of 0.62 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Twist Bioscience
3 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Veracyte currently has a consensus target price of $47.57, suggesting a potential downside of 11.56%. Twist Bioscience has a consensus target price of $71.60, suggesting a potential downside of 15.76%. Given Veracyte's higher probable upside, equities analysts clearly believe Veracyte is more favorable than Twist Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.56
Twist Bioscience
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summary

Veracyte beats Twist Bioscience on 10 of the 15 factors compared between the two stocks.

How does Veracyte compare to BrightSpring Health Services?

Veracyte (NASDAQ:VCYT) and BrightSpring Health Services (NASDAQ:BTSG) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Veracyte currently has a consensus price target of $47.57, suggesting a potential downside of 11.56%. BrightSpring Health Services has a consensus price target of $61.27, suggesting a potential downside of 8.34%. Given BrightSpring Health Services' stronger consensus rating and higher probable upside, analysts clearly believe BrightSpring Health Services is more favorable than Veracyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.56
BrightSpring Health Services
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
3.11

In the previous week, Veracyte had 6 more articles in the media than BrightSpring Health Services. MarketBeat recorded 9 mentions for Veracyte and 3 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 0.88 beat Veracyte's score of 0.62 indicating that BrightSpring Health Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BrightSpring Health Services
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BrightSpring Health Services has higher revenue and earnings than Veracyte. BrightSpring Health Services is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M8.30$66.35M$1.0949.35
BrightSpring Health Services$12.91B1.02$190.67M$1.4147.40

Veracyte has a beta of 1.98, meaning that its share price is 98% more volatile than the broader market. Comparatively, BrightSpring Health Services has a beta of 1.87, meaning that its share price is 87% more volatile than the broader market.

Veracyte has a net margin of 16.25% compared to BrightSpring Health Services' net margin of 2.27%. BrightSpring Health Services' return on equity of 14.63% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte16.25% 9.07% 8.38%
BrightSpring Health Services 2.27%14.63%4.41%

Summary

BrightSpring Health Services beats Veracyte on 9 of the 15 factors compared between the two stocks.

How does Veracyte compare to Fresenius Medical Care AG & Co. KGaA?

Veracyte (NASDAQ:VCYT) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Veracyte had 7 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 9 mentions for Veracyte and 2 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 0.85 beat Veracyte's score of 0.62 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fresenius Medical Care AG & Co. KGaA
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 1.4% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Veracyte has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Veracyte currently has a consensus price target of $47.57, suggesting a potential downside of 11.56%. Fresenius Medical Care AG & Co. KGaA has a consensus price target of $28.00, suggesting a potential upside of 17.99%. Given Fresenius Medical Care AG & Co. KGaA's higher probable upside, analysts clearly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Veracyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.56
Fresenius Medical Care AG & Co. KGaA
5 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.44

Veracyte has a net margin of 16.25% compared to Fresenius Medical Care AG & Co. KGaA's net margin of 4.88%. Veracyte's return on equity of 9.07% beat Fresenius Medical Care AG & Co. KGaA's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte16.25% 9.07% 8.38%
Fresenius Medical Care AG & Co. KGaA 4.88%8.90%4.05%

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Veracyte. Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M8.30$66.35M$1.0949.35
Fresenius Medical Care AG & Co. KGaA$22.20B0.58$1.11B$1.9012.49

Summary

Veracyte beats Fresenius Medical Care AG & Co. KGaA on 11 of the 17 factors compared between the two stocks.

How does Veracyte compare to Hims & Hers Health?

Veracyte (NASDAQ:VCYT) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Veracyte currently has a consensus target price of $47.57, indicating a potential downside of 11.56%. Hims & Hers Health has a consensus target price of $29.37, indicating a potential downside of 11.01%. Given Hims & Hers Health's higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than Veracyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.56
Hims & Hers Health
2 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.13

Veracyte has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.37, indicating that its stock price is 137% more volatile than the broader market.

Veracyte has a net margin of 16.25% compared to Hims & Hers Health's net margin of -0.56%. Veracyte's return on equity of 9.07% beat Hims & Hers Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte16.25% 9.07% 8.38%
Hims & Hers Health -0.56%6.10%1.52%

Hims & Hers Health has higher revenue and earnings than Veracyte. Hims & Hers Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M8.30$66.35M$1.0949.35
Hims & Hers Health$2.37B3.22$128.37M-$0.09N/A

In the previous week, Hims & Hers Health had 15 more articles in the media than Veracyte. MarketBeat recorded 24 mentions for Hims & Hers Health and 9 mentions for Veracyte. Hims & Hers Health's average media sentiment score of 0.81 beat Veracyte's score of 0.62 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Hims & Hers Health
11 Very Positive mention(s)
5 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

63.5% of Hims & Hers Health shares are owned by institutional investors. 1.4% of Veracyte shares are owned by insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Veracyte and Hims & Hers Health tied by winning 8 of the 16 factors compared between the two stocks.

How does Veracyte compare to PACS Group?

Veracyte (NASDAQ:VCYT) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

PACS Group has higher revenue and earnings than Veracyte. PACS Group is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$517.15M8.30$66.35M$1.0949.35
PACS Group$5.29B1.12$191.54M$1.5623.90

Veracyte has a net margin of 16.25% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Veracyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Veracyte16.25% 9.07% 8.38%
PACS Group 4.49%26.47%4.36%

In the previous week, PACS Group had 1 more articles in the media than Veracyte. MarketBeat recorded 10 mentions for PACS Group and 9 mentions for Veracyte. Veracyte's average media sentiment score of 0.62 beat PACS Group's score of -0.33 indicating that Veracyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veracyte
5 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PACS Group
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Veracyte presently has a consensus price target of $47.57, indicating a potential downside of 11.56%. PACS Group has a consensus price target of $48.00, indicating a potential upside of 28.72%. Given PACS Group's stronger consensus rating and higher possible upside, analysts plainly believe PACS Group is more favorable than Veracyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veracyte
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.56
PACS Group
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.71

Summary

PACS Group beats Veracyte on 8 of the 14 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VCYT vs. The Competition

Export
MetricVeracyteMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$4.24B$7.05B$6.44B$12.39B
Dividend YieldN/A1.28%2.69%5.83%
P/E Ratio49.3548.6524.9023.99
Price / Sales8.3076.50527.78108.89
Price / Cash35.7124.7844.8254.51
Price / Book3.257.1310.796.50
Net Income$66.35M$159.20M$3.56B$336.88M
7 Day Performance4.87%-0.98%1.00%-0.14%
1 Month Performance19.45%-1.97%0.42%0.77%
1 Year Performance100.11%5.08%29.70%28.49%

Veracyte Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCYT
Veracyte
2.1228 of 5 stars		$53.79
+1.1%		$47.57
-11.6%		+101.4%$4.24B$517.15M49.35790
TWST
Twist Bioscience
1.9669 of 5 stars		$80.79
+6.1%		$71.60
-11.4%		+140.6%$4.74B$376.57MN/A990
BTSG
BrightSpring Health Services
4.1558 of 5 stars		$64.08
+1.3%		$58.53
-8.7%		+193.5%$12.47B$12.91B45.4523,500
FMS
Fresenius Medical Care AG & Co. KGaA
4.2595 of 5 stars		$23.45
+1.8%		$28.00
+19.4%		-12.6%$12.43B$22.20B12.341,488
HIMS
Hims & Hers Health
3.0864 of 5 stars		$30.10
+12.2%		$28.70
-4.6%		-21.6%$6.21B$2.35BN/A2,442

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VCYT) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
My feud with Zohran Mamdani
Nearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...
Stansberry Research | Sponsoredtc pixel
Quick favor to ask you
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
Top Banks Warn: A Strange Day is Coming to America
Goldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...
TradeSmith | Sponsoredtc pixel
A drilling crew just broke a record nobody expected
A drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...
Behind the Markets | Sponsoredtc pixel
Read this before you touch SPCX
SPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...
Altimetry | Sponsoredtc pixel
Millionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.
Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...
Brownstone Research | Sponsoredtc pixel
Karp just filed Form 144
On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel